Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Donepezil 23 mg in Moderate to Severe Alzheimer's Disease
NCT02097056Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donepezil in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoint: Overall Summary of Adverse Events. Started Feb 2014; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02097056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097056.